V
Vt3

$Moderna(MRNA.US)

1️⃣ Exploded high after Moderna and Merck announced positive Ph3 result for their personalised mRNA melanoma cancer therapy, the first mRNA cancer treatment to achieve such a milestone. The news triggered a major short squeeze and a sharp re rating of Moderna’s future prospects.

2️⃣ I added a position cause the market narrative changed from a declining COVID company to a potential cancer treatment platform. One successful Ph3 trial can reshape future revenues expectations.

3️⃣ AI stocks depend mainly on earnings, adoption and valuation. MRNA depends on clinical, regulatory and pipeline milestones. In 2 months, I would gauge MRNA by follow through data and institutional support, not hype. 💊🩻🩺

图片 1,共 1 张
O
optionspuppy
Featured

📈 Why Do Stocks Rise on Good News?

A catalyst is news that changes investors’ expectations about a company’s future. Merck and Moderna’s positive Phase 3 melanoma trial is a good example. The treatment met its main goal and reduced the risk of cancer returning or death. This creates potential for regulatory submission, approval and future revenue. Investors may therefore believe the companies are worth more. However, good news does not guarantee a rise because the market may have already priced in the expectations.@Captain's Watch

WHY DO STOCKS RISE GOOD NEWS! < BECAUSE OF GOOD NEWS? A Beginner's Guide EXAMPLE
C
Captain's Watch
Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...